Physician profile
Aubrey Molgaard
NPI 1427597806
$237,558.98
in general payments reported to CMS, 2019-2025
21 companies · $87K in 2025
The $87K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.00 · 2022: $226 · 2023: $9,700 · 2024: $140K · 2025: $87K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $148K · Travel and Lodging: $70K · Food and Beverage: $15K · Honoraria: $3,600 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $147,993.38 |
| Travel and Lodging | $70,318.13 |
| Food and Beverage | $15,287.20 |
| Honoraria | $3,600.00 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $228,427.61 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $4,127.09 | 2022-2025 | Gvoke Hypopen |
| Sequel Med Tech, LLC | $1,704.55 | 2025 | Twiist |
| Novo Nordisk INC | $618.18 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $532.14 | 2023-2025 | Omnipod, Omnipod |
| Dexcom, INC. | $428.80 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $278.38 | 2022-2024 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.26 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $227.94 | 2023-2024 | |
| Amgen INC. | $207.51 | 2025 | Repatha, Krystexxa, Tepezza |
| Mannkind Corporation | $190.47 | 2025 | |
| Medtronic, INC. | $180.38 | 2023-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $128.69 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $100.89 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Corcept Therapeutics | $55.60 | 2024 | Korlym |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $26.40 | 2025 | Inspire |
| Mylan Specialty L.P. | $22.52 | 2024 | Yupelri |
| Lundbeck LLC | $20.59 | 2024 | Rexulti |
| Ascensia Diabetes Care US INC. | $16.55 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.85 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aubrey Molgaard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.